May 17, 2021 / 01:30PM GMT
Sasha Murray -
Hi, everyone. Thanks for joining us. Today, we have James Sapirstein, the Chairman and CEO of AzurRx. James?
James R. Sapirstein - AzurRx BioPharma, Inc. - President, CEO & Chairman of the Board
Thank you for inviting me to the conference. I'm happy to present AzurRx. This is our most recent presentation. As most company CEOs like to show you a company disclaimer, you might hear some information that you've not heard before, but keep this to yourself for now. So AzurRx is a NASDAQ company, it's a clinical stage company. We are specifically in the gastroenterology space. We have 2 assets, and we have 3 clinical indications. Our lead asset is MS1819. It's lipase for exocrine pancreatic insufficiency, or EPI. And we compete against PERTs, which are pancreatic enzyme replacement therapy products. We've actually done a lot of trials with this compound. It's a Phase II right now, and I'll get into some of that data in a few minutes.
Our second asset is a micronized niclosamide. Niclosamide is anthelmintic or antiparasite drug that's been around for
AzurRx BioPharma Inc at Investor Summit Group Virtual Summit Transcript
May 17, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers